Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enanta PharmaceuticalsSTU:9EP 58 PB Ratio is 3.31 as of Jul. 16, 2026, which is 33% above its 10-year median of 2.49. GuruFocus rates STU:9EP with a GF Score™ of 58/100 and a GF Value™ of €7.65 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,227 Biotechnology companies, Enanta Pharmaceuticals ranks worse than 55.01% on this metric.
The historical rank and industry rank for Enanta Pharmaceuticals's PB Ratio or its related term are showing as below:
STU:9EP'
s PB Ratio Range Over the Past 10 Years
Min: 0.8 Med: 2.49 Max: 6.91
Current: 3.3
During the past 13 years, Enanta Pharmaceuticals's highest PB Ratio was 6.91. The lowest was 0.80. And the median was 2.49.
STU:9EP's PB Ratio is ranked worse than 55.01% of 1227
companies
in the Biotechnology industry
Industry Median: 2.93
vs STU:9EP: 3.30
During the past 12 months, Enanta Pharmaceuticals's average Book Value Per Share Growth Rate was -8.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -41.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -33.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -10.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Enanta Pharmaceuticals was 32.00% per year. The lowest was -41.90% per year. And the median was 6.00% per year.
Back to Basics: PB Ratio
Enanta Pharmaceuticals (STU:9EP) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Enanta Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enanta Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Enanta Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Enanta Pharmaceuticals (STU:9EP) has a PB Ratio of 3.31 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Enanta Pharmaceuticals and its competitors. This is 33% above median its historical median of 2.49. Over the past decade, Enanta Pharmaceuticals' PB Ratio has ranged from 0.80 to 6.91. According to the industry distribution chart, Enanta Pharmaceuticals ranks #675 out of 1227 companies in the Biotechnology industry, placing it in the top 55%.
Is Enanta Pharmaceuticals' PB Ratio too high?
Enanta Pharmaceuticals' current PB Ratio of 3.31 is 33% above median its 10-year median of 2.49. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 6.91. The Biotechnology industry median PB Ratio is 2.93. Enanta Pharmaceuticals' value of 3.31 is 13% above this industry median. Based on the distribution chart, Enanta Pharmaceuticals ranks #675 out of 1227 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Enanta Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' PB Ratio compare to PBYI and IPSC?
According to the Biotechnology industry distribution chart, Enanta Pharmaceuticals ranks #675 out of 1227 companies for PB Ratio. This places Enanta Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.93. Enanta Pharmaceuticals' value of 3.31 is 13% above this benchmark. Historically, Enanta Pharmaceuticals' own PB Ratio has ranged from 0.80 to 6.91 over the past decade. While the company's 10-year median is 2.49 vs. the industry median of 2.93, Enanta Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enanta Pharmaceuticals's current PB Ratio of 3.31 is 13% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Enanta Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enanta Pharmaceuticals's current PB Ratio is 3.31, which is 33% above median its own 10-year median of 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.65, compared to a current price of €11.50 — trading 50.3% above its estimated fair value. The current PB Ratio is 3.31, which is 33% above median its 10-year median of 2.49 and 13% above the Biotechnology industry median of 2.93. Enanta Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current PB Ratio is 3.31 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?
Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued.
The current stock price of €11.50 is trading 50.3% above its estimated GF Value™ of €7.65.
GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for STU:9EP:
PB Ratio: 3.31 (33% above median its 10-year median of 2.49)
GF Value™: €7.65 vs. price of €11.50 (50.3% above fair value)
Industry Position: 13% above the Biotechnology median (#675 of 1227)
No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
58GF Score
Get the complete analysis for STU:9EP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:9EP has been successfully added to your 
